GLP-1 receptor agonists like Ozempic, originally designed for diabetes management, are gaining attention in addiction research. Scientists are investigating whether these medications could address substance dependency through novel neurobiological mechanisms. While some researchers show promising preliminary findings, others urge caution due to limited clinical evidence. This emerging field mirrors historical drug repurposing successes, highlighting how off-label applications sometimes unlock unexpected therapeutic benefits in treating complex behavioral disorders.

Summary auto-generated by AI from the original publisher's content. Editorial standards.